# **STRYX WORLD GROWTH**



### OBJECTIVE

Our objective is to achieve outstanding absolute returns with moderate risk by investing in OECD country companies of highest quality with proven track records, sound financials and predictability of future earnings growth.

These businesses typically have superior business models, stable and predictable business economics, a sustainable competitive advantage and high return on capital. They are run by a management team that exhibits high integrity and whose interests are closely aligned with long-term shareholders.

Following a detailed and proprietary analysis into these stocks, we assemble a portfolio of such companies which combines these quality and growth criteria.

#### **KEY DATA**

LEGAL STATUS: UCITS LIQUIDITY: Daily at NAV FUND INCEPTION DATE: 15/01/1996 (CHF Class) AVAILABLE CURRENCIES: USD/EUR/GBP/CHF FUND MANAGER: Raphaël Pitoun



LIPPER 🕕

### CONTACT

INVESTMENT MANAGER: Seilern Investment Management Ltd. WEBSITE: www.seilerninvest.com EMAIL: investorrelations@seilerninvest.com PHONE: +44 (0) 20 7494 1996




### COMMENTARY

The Stryx World Growth fund was up +3.4% in May, outperforming the MSCI World TR Index by +1.3%. Year to date, the fund is up +17.0% in absolute terms outperforming its benchmark by +6.8%. In May, out of the 23 positions in the fund, 19 stocks were up in absolute terms including 8 by more than +5%. The best performer was the IT services company Cognizant which was up +11.1%. The company published sound numbers at the start of the month as two divisions which weighted on last year's performance (healthcare and finance) started to normalize. The company also paid its first ever dividend in May. The second best performer was Ulta Beauty, up +8.3%. The company's organic growth and earnings development continue to surprise positively. Estée Lauder was the third best performer with the share price up +8.0%. Market participants are beginning to better understand all of the work done on the company's distribution channels; the results of Ulta also showed a recovery in the skin care segment as well as strong sales for Estée-owned brands Mac and Too Faced. Alphabet was up +6.8% with no particular news; the stock might have appreciated because of the enthusiasm for technology companies. Colgate, our last remaining position in consumer staples, was up +6.0% as some press reports mentioned potential interest from Kraft. The other good performers last month were respectively our smallest and largest positions in the fund: Novo Nordisk up +5.9% and Mastercard up +5.6%. The main detractors were Amgen, down -4.9%, Fanuc, down -3.9%, and Coloplast, down -3.0%. Amgen was down because of a setback with its bone density drug. The company's prospects are now increasingly tied to the success of its cholesterol drug. Fanuc was a strong performer until last month and we remain enthusiastic regarding the company's prospects (see our monthly newsletter). Finally, Coloplast was affected by results which were slightly disappointing, notably for the wound division.

### FUND PERFORMANCE (USD | Class)

| Net of Fees          | Fund   | MSCI World TR | Difference |
|----------------------|--------|---------------|------------|
| 1M                   | 3.4%   | 2.1%          | 1.3%       |
| 3M                   | 9.4%   | 4.7%          | 4.6%       |
| YTD                  | 17.0%  | 10.2%         | 6.8%       |
| 1Y                   | 16.9%  | 16.4%         | 0.4%       |
| 3Y                   | 38.7%  | 18.2%         | 20.5%      |
| 5Y                   | 111.6% | 79.5%         | 32.1%      |
| Inception 05/07/06   | 143.8% | 81.0%         | 62.7%      |
| CAGR 3Y              | 11.5%  | 5.7%          | 5.8%       |
| CAGR 5Y              | 16.2%  | 12.4%         | 3.8%       |
| CAGR Since Inception | 8.5%   | 5.6%          | 2.9%       |



All ratings and fund performance data relate to USD I Class. Further important information can be found on Page 3.

# **STRYX WORLD GROWTH**



## MONTHLY PERFORMANCE

| Net of Fees | Jan   | Feb    | Mar   | Apr   | May   | Jun   | July  | Aug   | Sep   | Oct    | Nov   | Dec   | YTD    |
|-------------|-------|--------|-------|-------|-------|-------|-------|-------|-------|--------|-------|-------|--------|
| 2017        | 3.2%  | 3.7%   | 1.8%  | 3.9%  | 3.4%  |       |       |       |       |        |       |       | 17.0%  |
| 2016        | -3.6% | -0.6%  | 7.7%  | 0.1%  | 1.3%  | -0.4% | 3.9%  | -0.6% | -0.4% | -3.5%  | -0.6% | 1.6%  | 4.5%   |
| 2015        | -1.7% | 8.0%   | 0.6%  | 1.0%  | 1.0%  | -1.8% | 4.1%  | -5.6% | -0.5% | 6.7%   | -1.0% | -0.1% | 10.2%  |
| 2014        | -2.1% | 6.0%   | -2.2% | -1.5% | 2.4%  | 0.1%  | -2.2% | 1.8%  | -0.9% | 1.4%   | 3.2%  | -0.5% | 5.3%   |
| 2013        | 5.4%  | 0.8%   | 1.3%  | 0.9%  | 1.5%  | -0.6% | 5.4%  | -1.4% | 5.6%  | 3.9%   | 4.3%  | 2.5%  | 33.7%  |
| 2012        | 2.5%  | 5.3%   | 3.8%  | -0.2% | -8.0% | 3.7%  | 0.7%  | 2.7%  | 4.0%  | -2.0%  | 1.5%  | 0.5%  | 14.6%  |
| 2011        | 1.5%  | 3.8%   | 0.0%  | 5.6%  | 0.3%  | -1.8% | -1.0% | -4.3% | -5.7% | 10.4%  | -1.6% | 0.5%  | 6.9%   |
| 2010        | -1.6% | 0.3%   | 4.6%  | -0.7% | -9.0% | -1.8% | 5.0%  | -3.4% | 9.7%  | 4.1%   | -3.4% | 4.9%  | 7.5%   |
| 2009        | -5.5% | -10.8% | 4.8%  | 10.5% | 4.8%  | 1.7%  | 6.1%  | 3.3%  | 2.1%  | 1.0%   | 4.9%  | 1.9%  | 25.6%  |
| 2008        | -6.5% | -0.9%  | -0.3% | 1.0%  | 2.4%  | -7.5% | 2.5%  | 2.7%  | -8.5% | -16.5% | -8.6% | 2.0%  | -33.7% |
| 2007        | 1.4%  | 1.4%   | -3.0% | 4.1%  | 1.7%  | -1.9% | -2.8% | 1.6%  | 1.6%  | 1.3%   | -0.6% | -2.2% | 2.5%   |
| 2006        |       |        |       |       |       |       | 0.1%  | 2.6%  | 1.5%  | 4.3%   | 3.0%  | 1.9%  | 14.1%  |

#### PORTFOLIO as at 28/02/2017

| Holdings                  | Portfolio |
|---------------------------|-----------|
| MasterCard                | 6.3%      |
| Priceline Group           | 6.2%      |
| Automatic Data Processing | 5.5%      |
| Dassault Systèmes         | 5.3%      |
| Colgate                   | 4.9%      |
| Stryker Corp              | 4.8%      |
| Amgen                     | 4.5%      |
| Cognizant                 | 4.4%      |
| Novozymes                 | 4.4%      |
| Accenture                 | 4.3%      |

| Sectors                | Portfolio |
|------------------------|-----------|
| Information Technology | 31.9%     |
| Health Care            | 16.7%     |
| Consumer Discretionary | 13.7%     |
| Consumer Staples       | 11.0%     |
| Industrials            | 9.8%      |
| Financials             | 7.9%      |
| Materials              | 4.4%      |
|                        |           |
|                        |           |

| Countries      | Portfolio |
|----------------|-----------|
| United States  | 64.2%     |
| Eurozone       | 11.3%     |
| Denmark        | 10.3%     |
| Switzerland    | 6.4%      |
| Japan          | 3.2%      |
| United Kingdom | 0.0%      |
| Cash           | 4.7%      |
|                |           |

## OPERATIONS

## SHARE CLASSES

| ••••••                          |   | · · · · · |              |            |                           |             |                         |       |      |  |  |
|---------------------------------|---|-----------|--------------|------------|---------------------------|-------------|-------------------------|-------|------|--|--|
|                                 |   | Class     | ISIN         | Bloomberg  | Price as at<br>31/05/2017 | Launch Date | CAGR<br>Since Inception | YTD   | 1M   |  |  |
| Fund size (USDm)                | 356.5   | USD I     | IEOOB5ST2S55 | STWDIUS ID | 248.0                     | 05/07/06    | 8.5%                    | 17.0% | 3.4% |  |  |
| Domicile                        | Ireland   | USD       | IEOOB5NUK73  | STWDUSD ID | 246.7                     | 29/06/01    | 6.1%                    | 14.7% | 2.6% |  |  |
| UCITS                           | Yes   | EURO U    | IEOOB2NXKW18 | STWDERU ID | 239.6                     | 01/01/08    | 10.5%                   | 9.3%  | 0.2% |  |  |
| Liquidity                       | Daily   | EURO      | IE0031724234 | STWDGRE ID | 192.7                     | 28/03/02    | 4.4%                    | 13.3% | 2.1% |  |  |
| Custodian                       | BBH +(353)16036490  | GBP I     | IEOOB4Z5CM38 | STWDGSI ID | 238.1                     | 19/09/12    | 20.3%                   | 11.9% | 3.9% |  |  |
| Turnover<br>(Average 2012-2016) | 20%   | GBP U     | IEOOB2NXKVO1 | STWDGBU ID | 373.4                     | 01/01/08    | 12.5%                   | 11.6% | 3.8% |  |  |
| TER (USD I class)               | 0.9%  | GBP       | IE0031724127 | STWDGRA ID | 269.0                     | 01/09/00    | 6.1%                    | 13.5% | 2.6% |  |  |
| Annual Fees                     | 0.75% (USD I/GBP I)<br>1.5% (other classes)<br>No performance fee | CHF       | IEOOB5WHP863 | STWDGRF ID | 232.3                     | 15/01/96    | 7.6%                    | 13.1% | 1.8% |  |  |

## **STRYX WORLD GROWTH**



## **Important Information**

NAVs are sourced from the Fund's custodians.

The Fund is a collective investment scheme that is a sub-fund of Seilern International Funds plc, an open-ended investment company umbrella fund with segregated liability between sub-funds, and registered and domiciled in Dublin, Ireland. In the United Kingdom it is a recognised scheme under s.264 Financial Services and Markets Act 2000 with the Financial Conduct Authority. Full details of the Fund objectives, investment policy and risks are located in the Prospectus which is available with the Key Investor Information Document in English and in an official language of the jurisdictions in which the Fund is registered, together with the Report and Accounts of the UCITS. The Fund's documentation are available free of charge from the Fund's investment manager, Seilern Investment Management Ltd. at mail@seilerninvest.com.

Past performance is not a reliable indicator of future results. Investments in any fund, sub-fund, security, financial instrument or product included in this communication are subject to certain risks and the value of an investment and any income derived from it can go down as well as up and investors may not get back their original amount invested. For detailed information on the specific risks to the Fund, please refer to the Fund's Prospectus.

This communication is for information purposes only and does not constitute an offer or invitation to invest in any fund, security, financial instrument or product for which Seilern Investment Management Ltd. provides investment advisory and/or investment management or any other services. The content does not represent and is not intended to constitute advice of any nature nor an investment recommendation or opinion regarding the appropriateness or suitability of any investment or strategy and does not consider the particular circumstances specific to any individual recipient to whom this material has been sent. Any data services and information available from public sources used in the creation of this communication are believed to be reliable. However accuracy is not warranted or guaranteed. Unless stated otherwise the source of all information is Seilern Investment Management Ltd. as of the date indicated above.

Opinions expressed are those of Seilern Investment Management Ltd. as of the date of this communication's publication, and are subject to change. Directors of Seilern Investment Management Ltd. may have direct or indirect holdings in the Fund.

Distribution of this communication and the availability of the Fund and/or any sub-funds may be restricted and the minimum subscription amount may be higher in certain jurisdictions. The product(s) mentioned within this communication (i) may not be registered for distribution in your jurisdiction, and (ii) may only be available to professional or otherwise qualified investors or entities. It is important that potential investors are able to ensure compliance with local regulations prior to making a subscription. Please refer to the offering documentation for additional information.

The Morningstar Ratings are referred to for information purposes only and should not be construed as an endorsement of the Fund or Seilern Investment Management Ltd. Please refer to the Morningstar website for information regarding the criteria on which the rating is determined. All information relating to a Morningstar Rating is proprietary to Morningstar and/or its content and its providers; and may not be copied or distributed; and is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Lipper Leaders fund ratings do not constitute and are not intended to constitute investment advice or an offer to sell or the solicitation of an offer to buy any security of any entity in any jurisdiction. As a result, you should not make an investment decision on the basis of this information. Rather, you should use the Lipper ratings for informational purposes only. Certain information provided by Lipper may relate to securities that may not be offered, sold or delivered within the United States (or any State thereof) or to, or for the account or benefit of, United States persons. Lipper is not responsible for the accuracy, reliability or completeness of the information that you obtain from Lipper. In addition, Lipper will not be liable for any loss or damage resulting from information obtained from Lipper or any of its affiliates.

This communication is issued by Seilern Investment Management Ltd., which is registered in England and Wales (Company Number 2962937) at 43 Portland Place London, W1B 1QH. Seilern Investment Management Ltd. is authorised and regulated by the Financial Conduct Authority. The fund is a Dublin Registered OEIC.

This communication is not suitable for US persons.